These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20922785)

  • 1. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
    Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D
    Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
    Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA
    Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
    Villaflor VM; Haraf D; Salama JK; Kocherginsky M; Langerman A; Gomez-Abuin G; Beniwal P; Blair EA; Stenson KM; Portugal L; Seiwert T; Williams RD; Dekker AJ; Witt ME; Vokes EE; Cohen EEW
    Ann Oncol; 2011 Nov; 22(11):2501-2507. PubMed ID: 21385883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
    von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
    Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
    Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
    Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
    Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
    Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
    Richey SL; Tamboli P; Ng CS; Lin E; Lim ZD; Araujo JC; Jonasch E; Sharma P; Pagliaro LC; Tannir NM
    Am J Clin Oncol; 2013 Oct; 36(5):450-4. PubMed ID: 22706175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
    Stover DG; Lockhart AC; Berlin JD; Chan E; Sandler AB; Sosman JA; Middlebrook V; Nicol S; Rothenberg ML
    Invest New Drugs; 2008 Aug; 26(4):339-45. PubMed ID: 18463792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
    Dreicer R; Li H; Cooney MM; Wilding G; Roth BJ;
    Cancer; 2008 Jun; 112(12):2671-5. PubMed ID: 18459175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
    Oettle H; Richards D; Ramanathan RK; van Laethem JL; Peeters M; Fuchs M; Zimmermann A; John W; Von Hoff D; Arning M; Kindler HL
    Ann Oncol; 2005 Oct; 16(10):1639-45. PubMed ID: 16087696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
    Kalykaki A; Vamvakas L; Agelaki S; Kalbakis K; Vardakis N; Sfakiotaki G; Ignatiadis M; Saridaki Z; Karampeazis A; Mavroudis D; Georgoulias V
    Oncology; 2006; 71(3-4):197-203. PubMed ID: 17641541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
    Dent SF; Gertler S; Verma S; Segal R; Young V; Goel R; Keller O; Canil C; Iscoe N
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):557-61. PubMed ID: 19593565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
    Scagliotti GV; Park K; Patil S; Rolski J; Goksel T; Martins R; Gans SJ; Visseren-Grul C; Peterson P
    Eur J Cancer; 2009 Sep; 45(13):2298-303. PubMed ID: 19473833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
    Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
    J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
    Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
    Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
    West HL; Wakelee HA; Perry MC; Belt RJ; Chen R; Obasaju C
    Ann Oncol; 2009 May; 20(5):850-6. PubMed ID: 19150937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.